Drug Trial Radar · NCT04556526
A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women
Last checked: Nov 19, 2026Latest source record: Feb 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,031
Actual
Start
Oct 5, 2020
Primary completion
Mar 2, 2023
Study completion Mar 2, 2023
Sponsor
- Lead sponsor
- Janssen Vaccines & Prevention B.V.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- Collaborators
- Center for Family Health Research (CFHR); Coalition for Epidemic Preparedness Innovations; Emory University
- First posted
- Sep 21, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is: a) to assess adverse maternal/fetal outcomes in pregnant women randomized to receive the 2- dose Ebola vaccine regimen (Ad26.ZEBOV, MVA-BN-Filo \[Group A\]) and in control women (unvaccinated pregnant women \[Group B\]); and b) to assess adverse neonatal/infant outcomes in neonates/infants born to women randomized to receive the 2-dose Ebola vaccine regimen (Ad26.ZEBOV, MVA-BN-Filo \[Group A\]) and in neonates/infants born to control women (unvaccinated during pregnancy \[Group B\]).
Conditions
- Healthy
Interventions
Ad26.ZEBOVBiological
Participants in Group A will receive 0.5 mL IM injection of Ad26.ZEBOV vaccine. Participants in Group B will receive Ad26.ZEBOV 6 weeks after delivery/termination of pregnancy.
MVA-BN-FiloBiological
Participants in Group A will receive 0.5 mL IM injection of MVA-BN-Filo vaccine. Participants in Group B will receive MVA-BN-Filo 6 weeks after delivery/termination of pregnancy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with Maternal DeathsTime frame: Up to 6 weeks post-completion/termination of pregnancy
- Percentage of Participants with Spontaneous AbortionTime frame: Up to 6 weeks post-completion/termination of pregnancy
- Percentage of Participants with StillbirthTime frame: Up to 6 weeks post-completion/termination of pregnancy
- Percentage of Participants on the Pathways to Preterm BirthTime frame: Up to 6 weeks post-completion/termination of pregnancy
- Percentage of Participants with Pre-eclampsia/ eclampsiaTime frame: Up to 6 weeks post-completion/termination of pregnancy
- Percentage of Participants with Antenatal BleedingTime frame: Up to 6 weeks post-completion/termination of pregnancy
- Percentage of Participants with Postpartum HemorrhageTime frame: Up to 6 weeks post-completion/termination of pregnancy
- Percentage of Newborns with Major Congenital Malformations born to ParticipantsTime frame: At birth
- Percentage of Newborns Small for Gestational age (SGA) born to ParticipantsTime frame: At birth
- Percentage of Newborns with Low Birth Weight born to ParticipantsTime frame: At birth
- Percentage of Newborns with Preterm Birth born to ParticipantsTime frame: At birth
- Percentage of Neonatal Deaths in Neonates Born to ParticipantsTime frame: Up to 28 days
- Percentage of Infants (of Participants) who Fail to ThriveTime frame: From birth up to 14 weeks of age
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Gihundwe District Hospital
Cuangugu, Rwanda
Gisenyi Hospital
Gysenyi, Rwanda
Center for Family Health Research/Project San Francisco
Kigali, Rwanda
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.